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ABSTRACT 
Objective: Dimethyl fumarate (DMF) is a methyl ester of fumaric acid. It has been approved by USFDA recently for the treatment of an autoimmune 
disorder, multiple sclerosis (MS). The objective of present study was to synthesize and optimize chitosan loaded nanoparticles of DMF by box-
behnken design (BBD), to provide a better drug delivery system for the management and treatment of MS. 
Methods: Polyelectrolyte complex coacervation technique was used to prepare Chitosan (CS) loaded DMF nanoparticles and box behnken design 
using 3 factors and 3 levels were selected for optimization of the formulation. Effect of three independent factors that is, polymer CS concentration, 
polymer dextran sulfate (DS) concentration and the amount of drug were studied on two dependent responses that is particle size and % drug 
entrapment efficiency. The analysis of variance (ANOVA) was performed to evaluate the significant differences between the independent variables.  
Results: The optimized batch showed the highest % drug entrapment (65.36) and an average particle size (355 nm). Zeta potential value was 
optimum to maintain the stability of the formulation. In vitro drug release behavior followed Korsmeyer-Peppas model which showed the initial 
release of 21.7±1.3% with prolonged drug release of 69.5±0.8% from optimized CS nanoparticle up to 24 h. The % cumulative drug release (% CDR) 
of optimized nanoparticles was 84%. 
Conclusion: The optimized nanoparticles of DMF with improved properties could be a promising formulation for the treatment and management of MS.  
Keywords: Multiple sclerosis, dimethyl fumarate, chitosan nanoparticle, optimization, box behnken design, complex polyelectrolyte conservation. 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2016v8i4.13450 
 
INTRODUCTION 
Nanoparticles represent an effective nanocarrier platform for the 
delivery of hydrophilic and hydrophobic drugs since the drugs are 
protected from possible degradation by enzymes [1].  
MS is an autoimmune disease the body’s own immune system 
spearheads the attacks. The disorder is mediated by a complex 
interaction of individual’s genetics and as yet unidentified 
environmental insults. In multiple regions, the myelin sheaths 
deteriorate to sclerosis, which are hardened scar or plaques [2, 3]. 
Nanotechnology by manipulation of characteristics of materials such 
as polymers and fabrication of nanostructures is able to provide 
superior drug delivery systems for better management and 
treatment of diseases [2]. Drug targeting by nanoparticles has been 
getting much attention by the researchers for the treatment of 
various central nervous system disorders [4]. DMF is a white, 
nonhygroscopic BCS class 1 drug [5]. DMF has been approved by 
USFDA in 2014 as the first-line oral treatment for Multiple Sclerosis 
[6]. DMF is almost completely absorbed in the small intestine and 
extensively metabolized by esterases before it reaches the systemic 
circulation. The half-life of DMF is approximately 1 hour. CS is a 
promising candidate for preparation of nano and microparticulate 
drug delivery systems owing to its low toxicity, better stability, 
simple and reproducible preparation methods and provides 
versatile routes of administration as drug delivery carrier [7]. CS is 
one of the most abundant biopolymers, poly [β-(1,4)-2-amino-2-
deoxy-d-glucopyranose], possesses unique structural features. In the 
present method, an organic phase containing the polymer and drug 
is added dropwise to a dispersing phase which is a nonsolvent for 
the dispersed polymer but is miscible with the diffusing solvent. The 
formation of nanoparticles happens spontaneously [8]. This method 
does not require vigorous shearing or stirring rates, ultrasonication 
and is mostly suitable for the compounds having hydrophobic 
nature [9-11]. In the present study, CS loaded DMF nanoparticles 
were formulated and optimized by box-behnken design. This work 
has a novel and promising approach for the use of DMF in the 
treatment and management of MS. 
MATERIALS AND METHODS 
Materials 
CS (degree of acetylation=80.45%) and dextran sulphate (DS) were 
procured from chemsworth chemicals, Surat. DMF was obtained 
from Alfa Aesar; a Johnson matthey company. Methanol, glacial 
acetic acid, and acetone were of the suitable analytical grade. Double 
distilled water was used in the preparation of solutions and 
dispersion of chitosan nanoparticles.  
Preparation of CS DS nanoparticle 
CS Nanoparticles were prepared by polyelectrolyte complex 
coaservation technique [12-15]. A solution of CS was prepared by 
dissolving required quantity of CS in 2% v/v acetic acid solution. DS 
solution was prepared by dissolving required quantity of DS in 
double distilled water. To DS solution required a quantity of DMF 
was added and dissolved completely. Now DS containing dissolved 
drug solution was added dropwise to CS solution under magnetic 
stirrer for 1 hour. Tween 80 was added to stabilize the resultant 
particles followed by continuous stirring. The ratio between the 
volumes of DS Solution and CS solution was 1:4. The nanoparticle 
batches were prepared as per box-behnken design. 
Optimization of CS nanoparticles by box Behnken design 
Design Expert® 9.0.5.1 software was used to developing a box-
behnken statistical design, response surface methodology (RSM) with 
3 factors, 3 levels, and 15 runs for the optimization of CS nanoparticles 
[16-18]. Optimization was performed to investigate the level of 
independent variables (X1, X2, and X3) that would yield a minimum 
value of the particle size (R1) and the maximum value of EE (R2). The 
design was used to explore the quadratic response surfaces, and the 
polynomial equation was generated by the experimental design is as 
follows:  
Y = b0 + b1x1 + b2x2 + b3x3 + b12x1x2 + b13x1x3 + b23x2x3
+ b11X1
21
1 + b22X2
21
1 + b33X3
21
1 
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Where Y is the independent variable, b0 is the intercept and b1, b2, 
b3 are regression coefficients which were calculated from the 
experimental results of independent variables and dependent 
variables. The independent variables were a concentration of CS 
(X1), the concentration of DS (X2) and concentration of DMF (X3) 
and dependent variables was particle size (R1) and entrapment 
efficiency (% EE) (R2) with high, medium and low level. The 
independent and dependent variables are listed in table 1 and 
table 2 respectively. The box behnken design was used with 3 
formulation variables at 3 levels and all the batches of CS 
nanoparticles were evaluated statistically (p<0.05). A checkpoint 
analysis was performed to confirm the role of the derived 
polynomial equation and contour plots in prediction the responses 
[19, 20]. 
 
Table 1: Independent variables 
Independent variables level 
-1 0 +1 
A % CS (w/v) 0.025 0.0625 0.1 
B % DS (w/v) 0.02 0.04 0.06 
C % Drug amount (w/v) 0.1 0.3 0.5 
 
Table 2: Dependent variables 
Dependent variables Constraints 
R1 (Particle Size) Minimum 
R2 (% EE) Maximum 
 
Characterization of DMF loaded nanoparticles 
Size determination 
The average particle diameter, polydispersity index (PDI) and zeta 
potential of the polymeric nanoparticles were determined by 
dynamic light scattering (DLS) analysis using Zeta Sizer Nano ZS90 
(Malvern Instruments Limited, U. K.) The samples of CS nanoparticle 
were placed in disposable cuvettes for size and zeta potential 
measurement. The nanoparticles were dispersed in an appropriate 
volume of HPLC grade water at 25 °C, at a detection angle of 90 ° for 
measuring the size and PDI and 120 ° for zeta potential 
measurement. 
Drug entrapment efficiency (% EE) 
DMF loaded nanoparticles were separated from the solution by 
centrifugation 2000 rpm for 1 hour. Supernatants recovered from 
centrifugation were decanted. DMF content in the supernatant was 
analyzed by a UV-Vis spectrophotometer (Shimadzu UV 2700) at 
208 nm. The percentage drug entrapment efficiency (%EE) was 
calculated using the following formula [21, 22]. 
% EE = [Total amount of DMF added − Free DMF in supernatant
÷ Total amount of DMF] × 100  
In vitro drug release 
In vitro drug release study of the optimized DMF loaded CS 
nanoparticles was carried out using the equilibrium dialysis 
technique at 37±1 °C. Nanoparticles (equivalent to 1 mg DMF) were 
suspended in 5 ml of phosphate buffer (PBS) having pH 7.4 and 
placed in a dialysis membrane bag. The membrane bag containing 
DMF loaded CS nanoparticle suspension was placed in 500 ml PBS. 
The agitation speed was set at 50 rpm. At regular time intervals, 5 
ml of the aliquots were collected and replaced with an equal 
volume of fresh PBS to maintain the sink condition. The collected 
aliquots were centrifuged, and the supernatant was analyzed to 
calculate the % release of DMF using UV-Visible Spectro-
photometer at 208 nm. In vitro drug release study was also 
performed using 0.1 N HCl as dissolution fluid. All the experiments 
were repeated in triplicate. 
FT-IR spectroscopy 
In order to evaluate the chemical interaction between CS, DS and 
DMF spectra of the pure CS, pure DS, pure DMF and optimized 
nanoparticle were obtained (by KBr Pellet Method) on FT-IR (Perkin 
Elimer Spectrum II). 
Electron microscopic examination 
The optimized batch of nanoparticles was formulated and examined 
under scanning electron microscope (SEM) on FEI quanta 250 to 
study the morphology of prepared nanoparticles. 
RESULTS AND DISCUSSION 
Total 15 runs as per BBD and 3 checkpoint batches were formulated. 
Different concentrations of CS, DS and DMF were used to optimize 
the best concentration on the basis of % entrapment efficiency and 
particle size. The observed values of both dependent variables that 
are particle size and % EE are shown in the table 3. 
 
Table 3: Result showing effect of independent variables on responses (mean value±SD) (n=3) 
Run Factor 1  
A % CS(w/v) 
Factor 2 
B % DS (w/v) 
Factor 3 
C %Drug amount (w/v) 
Response 1 
Size (nm) 
Response 2 
% EE 
Batch 1 0 0 0 245±1.8 68±0.25 
Batch 2 -1 -1 0 365±2.6 53±0.43 
Batch 3 1 0 1 235±1.4 69±0.52 
Batch 4 1 0 -1 238±1.6 67±0.32 
Batch 5 0 1 1 255±2.1 58±0.62 
Batch 6 1 -1 0 240±2.6 54±0.53 
Batch 7 0 -1 -1 260±1.5 56±0.72 
Batch 8 0 1 -1 258±1.7 58±0.24 
Batch 9 1 1 0 242±1.8 70±0.32 
Batch 10 -1 0 1 364±2.0 52±0.26 
Batch 11 -1 0 -1 358±2.1 50±0.23 
Batch 12 0 -1 1 264±1.6 54±0.83 
Batch 13 0 0 0 245±1.7 68±0.62 
Batch 14 -1 1 0 362±1.4 55±0.33 
Batch 15 0 0 0 245±1.9 68±0.62 
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Effect of independent variables on particle size 
Polymer concentration affects particle size and release of drug from 
the nanoparticle matrix. Average particle size of developed 
nanoparticles was found in the range of 235 nm (Batch 3) to 365 nm 
(Batch 2) for different variable combinations. The effect on -
average can be explained by the following quadratic equation:  
Size = 245.00 − 11.75 × A − 1.50 × B + 0.50 × c + 1.25 × AB
− 2.25 × AC − 1.75 × BC − 1.62 × A2 + 8.88
× B2 + 5.37 × C2 
The Model F-value 0f 57.85 and prob>F less than 0.05 implies the 
model is significant. The predicted R-squared is in a reasonable 
range with the adjusted R-squared with a difference of less than 0.2. 
Effect of independent variable on % entrapment efficiency 
(% EE) 
The percentage drug entrapment of developed nanoparticles was 
found in the range of 52 (Batch 10) to70 (Batch 9). Final quadratic 
equation for prediction of % EE is as follows:  
% EE = 68.00 + 6.25A + 3.00B + 0.25C + 3.5AB − 5.55AC + 0.05BC
− 3.50A2 + 6.5B2 − 5.00C2 
The Model F-value of 6.11 implies the model is significant again 
prob>F, less than 0.05 implies the model terms are significant. 
Checkpoint analysis 
A total of three checkpoint DMF loaded CS nanoparticle formulations 
were prepared and evaluated for the responses. Predicted values 
were also calculated from the polynomial equation and compared 
with measured values. 
As per the optimization results of BBD the independent variables for 
optimized batch are % CS is 0.651 w/v, % DS is 0.481 w/v and % 
DMF is 0.502 w/v. The predicted values of responses are average 
particle size is 334.63 nm and % drug entrapment efficiency of 69.47 
(fig. 1). DMF loaded CS nanoparticles were formulated with 
optimized concentration and evaluated for % EE and average 
particle size. % EE of the optimized batch was found to be 65.36% 
and average particle size was found to be 355 nm which is in good 
correlation with predicted values of responses. 
 
Table 4: Checkpoint batches with predicted and measured value (mean value±SD)(n=3) 
Batch code Factor 1 
% CS 
Factor 2 
% DS 
Factor 3 
% Drug 
Particle size % EE 
Predicted Measured Predicted Measured 
CP1 1 0 -1 260 248±1.23 56 52±0.15 
CP2 0 0 1 235 230±1.4 69 63±0.24 
P value    0.986  0.965  
 
 
Fig. 1: Graph showing correlation between predicted and actual results 
 
 
Fig. 2: 3D response surface plot showing effect of % CS and DS on size 
Design-Expert® Software
Size
Color points by value of
Size:
265
235
Actual
Pr
ed
ict
ed
Predicted vs. Actual
230
240
250
260
270
230 240 250 260 270
Design-Expert® Software
Factor Coding: Actual
Size (nm)
Design points above predicted value
Design points below predicted value
265
235
X1 = A: % CS
X2 = B: % DS
Actual Factor
C: Drug amount = 0
-1  
-0.5  
0  
0.5  
1  
  -1
  -0.5
  0
  0.5
  1
220  
230  
240  
250  
260  
270  
Si
ze
 
(nm
)
A: % CS (% w/v)B: % DS (% w/v)
Ojha et al. 
Int J App Pharm, Vol 8, Issue 4, 2016, 10-17 
 
13 
 
Fig. 3:3D response surface plot showing effect of % CS and drug amount on size 
 
 
Fig. 4: 3 D response surface plot showing effect of % drug amount and % DS on size 
 
 
Fig. 5: 3-D response surface plot showing effect of % CS and % DS on % EE 
 
 
Fig. 6: 3-D response surface plot showing effect of % CS and Drug amount on % EE 
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Fig. 7: 3D response surface plot showing effect of % DS and drug amount on % EE 
 
Drug-excipient compatibility 
In FTIR study it was observed that there was no interaction between 
DMF and the polymers. DMF is compatible with the nanoparticle 
components. 
In vitro drug release study 
In vitro drug release was analyzed by dialysis method and the data 
was expressed as mean±SD where n = 3 (fig. 8). The release data was 
fitted with different kinetic models of dissolution such as zero order, 
first order, Higuchi and Korsmeyer-Peppas model (table 5). 
The cumulative % drug release for an optimized batch of DMF 
loaded chitosan nanoparticle was 84% over a period of 24 h. 
Korsmeyer-peppers model was observed to be a best fit model with 
R2 value 0.981 on 0.1 N HCl and 0.923 in 7.4 PBS. 
 
Fig. 8: In vitro drug release profile of optimized CS 
nanoparticles (n=3) 
 
Table 5: Release kinetics of chitosan nanoparticles of the optimized batch (mean value±SD), n=3 
Dissolution medium Zero order First order Hixson Higuchi Korsmeyer-Peppas 
k R2 k R2 k R2 k R2 k R2 
0.1N HCL 2.558 0.835 0.017 0.911 0.053 0.882 14.18 0.950 0.616 0.981 
7.4 PBS 2.429 0.916 0.016 0.851 0.649 0.896 13.32 0.9488 0.677 0.923 
 
 
Fig. 9: FTIR of pure chitosan 
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Fig.10: FTIR of pure DMF 
 
 
Fig. 11: FTIR of pure dextran sulphate 
 
 
Fig. 12: FTIR of optimized DMF loaded CS nanoparticles 
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The aim of present study was to synthesize and optimize a 
biocompatible CS-DS nanoparticle of DMF for the treatment and 
management of MS. DMF loaded CS-DS nanoparticles can be 
produced by the polyelectrolyte complex coacervation technique 
and tween 80 was used to prevent the aggregation of nanoparticles 
prepared by above method. The particle size was found to be 
increased with increasing amount of polymer DS and CS. An 
equimolar ratio of drug and both the polymers yield an optimum 
sized nanoparticle. The average zeta potential value is-40 mv which 
is optimum to maintain the stability of nanoparticles at an equimolar 
ratio. All the measured zeta potential values for different batches are 
negative. A negative zeta potential indicates the CS-DS coating of 
DMF nanoparticles. A higher value of zeta potential implies that high 
energy will be needed to bring two particles in contact. Thus the 
prepared CS-DS coated DMF nanoparticles have a high energy 
barrier for the aggregation of nanoparticles. The entrapment 
efficiency was also improved with the use of tween 80. 
In vitro release kinetics was fitted with dissolution models zero. 
First, hixon, Higuchi and Korsmeyer-peppers and on the basis of the 
correlation coefficient (R2) value the best fit model was selected. 
Korsmeyer-peppers model showed a higher R2 value and the n value 
indicated that release kinetics follows diffusion coupled with 
polymer matrix relaxation. Results of SEM image showed that the 
particles are spherical in shape with a smooth surface. The particle 
size varied from 240 to 320 nm. 
 
 
Fig. 13: SEM image of optimized batch 
 
 
Fig. 14: Particle size distribution of optimized batch 
 
 
Fig. 15: Zeta potential of optimized batch 
CS is a biocompatible and natural biodegradable polymer which 
shows its compatibility with entrapped DMF. Based on the results it 
is clear that an equimolar ratio of CS and DS produces a nanoparticle 
formulation with least particle size and an optimum zeta potential. 
All optimized nanoparticles showed a mean diameter of 320 nm and 
thus these are a promising formulation to reduce the side effects of 
currently available tablet and pellets of DMF. 
CONCLUSION 
In the present study, a novel nanoparticle formulation of DMF was 
investigated. The effect of three independent variables which are a 
concentration of CS, concentration of DS and amount of DMF was 
investigated on two dependent variables which are particle size and % 
entrapment efficiency. An optimized batch of nanoparticles was 
formulated and characterized as per RSM. The observed values were 
found to be promising when compared with the design expert 
software results. The in vitro release kinetics shows a controlled and 
sustained release profile. From the present research work it could be 
concluded that DMF nanoparticles can be successfully prepared with 
CS and DS polymers. The SEM image also confirms the formation of 
smooth and spherical nanoparticles. The prepared nanoparticles carry 
a good poly dispersibility index and zeta potential values. 
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